EcoDrugPlus

Fibroblast Activation Protein Alpha

Ensembl ID : ENSBBBG00000014785
Gene Symbol: FAP
3 Cross references
127 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSBBBG00000025401
Gene Symbol: FGF2
1 Cross references
117 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSBBBG00000023016
Gene Symbol: FGFR1
3 Cross references
293 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSBBBG00000010374
Gene Symbol: FGFR2
3 Cross references
216 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSBBBG00000008640
Gene Symbol: FGFR3
1 Cross references
196 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSBBBG00000010620
Gene Symbol: FGFR4
3 Cross references
122 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSBBBG00000012485
Gene Symbol: FLT1
3 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSBBBG00000012586
Gene Symbol: FLT3
3 Cross references
134 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSBBBG00000001895
Gene Symbol: FLT4
3 Cross references
198 Possible Orthologues:

Folate Hydrolase 1

Ensembl ID : ENSBBBG00000019191
Gene Symbol: FOLH1
3 Cross references
211 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSBBBG00000012015
Gene Symbol: FSHR
3 Cross references
200 Possible Orthologues:

Free Fatty Acid Receptor 1

Ensembl ID : ENSBBBG00000023761
Gene Symbol: FFAR1
3 Cross references
76 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).